Dr Ian Brock
Clinical Medicine, School of Medicine and Population Health
Breast Cancer Tissue Technician
i.w.brock@sheffield.ac.uk
+44 114 215 9085
+44 114 215 9085
GU18, G Floor, The Medical School
Full contact details
Dr Ian Brock
Clinical Medicine, School of Medicine and Population Health
GU18, G Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Clinical Medicine, School of Medicine and Population Health
GU18, G Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Publications
-
Show: Featured publications All publications
Featured publications
This person does not have any publications available.
All publications
Journal articles
- Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study. Bone Marrow Transplantation. View this article in WRRO
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 52(1), 56-73. View this article in WRRO
- Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 120, 647-657. View this article in WRRO
- Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. The American Journal of Human Genetics, 104(1), 21-34. View this article in WRRO
- Genome-wide analysis of circulating cell-free DNA copy number detects active melanoma and predicts survival. Clinical chemistry, 64(9), 1338-1346. View this article in WRRO
- Association analysis identifies 65 new breast cancer risk loci. Nature, 551, 92-94. View this article in WRRO
- Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and “BRCA-Like” Status, in Both Blood and Tumour DNA. PLoS One, 11(7). View this article in WRRO
- Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus. Cancer Research, 76(7), 1916-1925. View this article in WRRO
- Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. The Journal of Pathology: Clinical Research, 1(1), 18-32. View this article in WRRO
- FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. British Journal of Cancer, 110(4), 1088-1100. View this article in WRRO
- A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 23(7), 1934-1946.
- Identification of candidate driver genes in common focal chromosomal aberrations of microsatellite stable colorectal cancer.. PLoS One, 8(12), e83859-e83859. View this article in WRRO
- The common PARK8 mutation LRRK2 G2019S is not a risk factor for breast cancer in the absence of Parkinson’s disease. Journal of Neurology, 260(8), 2177-2178.
- Associations of ATR and CHEK1 Single Nucleotide Polymorphisms with Breast Cancer. PLoS ONE, 8(7). View this article in WRRO
- Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 45(4), 353-361.
- 1. Hypermethylation of distinct CpG islands within the BRCA1 promoter is associated with triple negative phenotype breast cancer. European Journal of Surgical Oncology (EJSO), 38(11), 1134-1134.
- A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients. SpringerPlus, 1(1). View this article in WRRO
- Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 7(6). View this article in WRRO
- 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 33(7), 1123-1132.
- Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. British Journal of Cancer, 105(12), 1934-1939. View this article in WRRO
- Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer. Cancer Epidemiology, Biomarkers & Prevention, 20(10), 2222-2231.
- 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. Journal of Medical Genetics, 48(10), 698-702.
- Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiology, Biomarkers & Prevention, 19(9), 2143-2151.
- Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor–Negative Breast Cancer Survival. JNCI: Journal of the National Cancer Institute, 102(9), 650-662.
- Risk of Estrogen Receptor–Positive and –Negative Breast Cancer and Single–Nucleotide Polymorphism 2q35-rs13387042. JNCI: Journal of the National Cancer Institute, 101(14), 1012-1018.
- A Breast Cancer Risk Haplotype in the Caspase-8 Gene. Cancer Research, 69(7), 2724-2728.
- Genome-wide association study identifies novel breast cancer susceptibility loci. NATURE, 447(7148), 1087-1093.
- Meningiomas, dicentric chromosomes, gliomas, and telomerase activity. The Journal of Pathology, 188(4), 395-399.
Conference proceedings papers
- Copy-number profiles from circulating cell-free DNA as a potential biomarker in melanoma. European Journal of Surgical Oncology, Vol. 44 (pp S26-S27)
- Copy-number profiles from circulating cell-free DNA as a potential biomarker in melanoma. European Journal of Surgical Oncology, Vol. 43(11) (pp 2225-2225)
- Circulating cell-free DNA copy-number profiles as a biomarker in melanoma. European Journal of Surgical Oncology (EJSO), Vol. 42(11) (pp S245-S245)
- Multicentre study of CASP8 polymorphisms in breast cancer. Breast Cancer Research, Vol. 10(S2) View this article in WRRO